ELANA® Bypassing open heart surgery with Excimer Laser Assisted Non Occlusive Anastomosis (ELANA®)
- Coordinator
- Amt Medical Research BV, Netherlands
- Runs
- 1 October 2022 to 30 September 2025
- Status
- Running
- EU funding
- €2.5m
- Total cost
- €3.6m
- Partners
- 2 organisations in 1 countries
- Type
- European Innovation Council
- Grant agreement
- 190101904
What the project is doing
In the project's own words, from its summary on CORDIS.
We will revolutionise the medical field by replacing expensive, invasive and high-risk open-heart surgery, with “keyhole” minimally invasive surgery (MIS) to treat coronary artery disease (CAD). Our ELANA® technology enables reproducible coronary artery bypass grafting (CABG) surgery without the need of heart arrest and suturing, thus avoiding the need to open the patient’s chest. This is realised with an innovative clip which circumvents the need of suturing of blood vessels altogether.
By realising closed-chest CABG, ELANA® reduces not only the risks associated with traditional CABG, such as bleeding, stroke and wound infection, but also significantly shortens recovery times. As a result, ELANA® will reduce direct healthcare costs of CABG procedures by over 50%. To critically de-risk our technological development and accelerate market entry to 2025, AMT Medical seeks a total of €7.5M funding (€2.5M grant, €5M equity) to finalise clinical validation and gain market approval.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Amt Medical Research BV | Utrecht | Netherlands | Coordinator |
| AMT Medical BV | Ede | Netherlands | Third party |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI